Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo(Columbia University Irving Medical Center), Wildon Farwell(Biogen (United States)), Douglas A. Kerr(Tampa General Hospital), Gabriel Braley(Biogen (United States)), Janbernd Kirschner(University of Freiburg), Monique M. Ryan(Royal Children's Hospital), Nancy L. Kuntz(Lurie Children's Hospital), Valeria Sansone(University of Milan), Thomas O. Crawford(Johns Hopkins University), Stephanie Fradette(Biogen (United States)), Francy Shu(University of California, Los Angeles), Yuh‐Jyh Jong(National Yang Ming Chiao Tung University), Marco Petrillo(Biogen (United States)), Wuh‐Liang Hwu(MRC Epidemiology Unit), Tawfeg Ben‐Omran(Qatar Airways (Qatar)), Christopher Stebbins(University of Illinois Chicago), Enrico Bertini(Bambino Gesù Children's Hospital), Sandra P. Reyna(Novartis (United States)), Russell J. Butterfield(University of Utah), Ishir Bhan(Harvard University Press), Sarah Gheuens(Biogen (United States)), Kathryn J. Swoboda(Massachusetts General Hospital), John F. Staropoli(Biogen (United States)), Richard S. Finkel(St. Jude Children's Research Hospital), Haluk Topaloğlu(Yeditepe University), Julie Parsons, Alfred Sandrock(Biogen (United States)), Kristina Johnson(Biogen (United States)), Richard Foster(Massachusetts Institute of Technology)
Cited by 636
Related Papers
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k